Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 30;20(8):1852–1858. doi: 10.1111/jth.15757

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Cumulative incidence of thrombosis in autoimmune hemolytic anemia (AIHA) patients. (A) Cumulative incidence of thrombosis (continuous line) and of mortality (dashed line). (B–D) Cumulative incidence of thrombosis in panel B. Patients treated with rituximab (continuous line) or not (dashed line); panel C. Patients with LDH ≥1.5× upper limit of normality, ULN (continuous line) or not (dashed line); panel D. Patients treated with cyclophosphamide (continuous line) or not (dashed line); panel E. Patients who underwent blood transfusions (continuous line) or did not (dashed line); panel F. Patients experiencing infections (continuous line) or not (dashed line).